|
gptkbp:instanceOf
|
gptkb:antibiotic
gptkb:drug
|
|
gptkbp:affiliatedWith
|
gptkb:rifamycin_antibiotics
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A07AA11
|
|
gptkbp:bioavailability
|
<1% (oral)
|
|
gptkbp:brand
|
gptkb:Xifaxan
|
|
gptkbp:CASNumber
|
80621-81-4
|
|
gptkbp:chemicalFormula
|
C43H51N3O11
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to rifaximin
|
|
gptkbp:discoveredBy
|
gptkb:Alfa_Wassermann
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rifaximin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial RNA synthesis
|
|
gptkbp:metabolism
|
minimal systemic absorption
|
|
gptkbp:molecularWeight
|
785.9 g/mol
|
|
gptkbp:origin
|
semisynthetic derivative of rifamycin SV
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
67.5%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
constipation
headache
|
|
gptkbp:usedFor
|
gptkb:hepatic_encephalopathy
irritable bowel syndrome with diarrhea
traveler's diarrhea
|
|
gptkbp:bfsParent
|
gptkb:rifamycin_antibiotics
gptkb:hepatic_encephalopathy
|
|
gptkbp:bfsLayer
|
6
|